Abstract
Atropine, the classic muscarinic receptor antagonist, inhibits ion currents mediated by neuronal nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes. At the holding potential of −80 mV, 1 μm atropine inhibits 1 mm acetylcholine-induced inward currents mediated by rat α2β2, α2β4, α3β2, α3β4, α4β2, α4β4, and α7 nicotinic receptors by 12–56%. Inward currents induced with a low agonist concentration are equally inhibited (α3β2, α3β4), less inhibited (α2β4, α7), or potentiated (α4β2, α4β4) by 1 μm atropine. Effects on the more sensitive α4β4 nicotinic receptors were investigated in detail by systematic variation of acetylcholine and atropine concentrations and of membrane potential. At high agonist concentration, atropine inhibits α4β4 nicotinic receptor-mediated ion current in a noncompetitive, voltage-dependent way with IC50 values of 655 nm at −80 mV and of 4.5 μm at −40 mV. At low agonist concentration, 1 μm atropine potentiates α4β4 nicotinic receptor-mediated ion current. This potentiating effect is surmounted by high concentrations of acetylcholine, indicating a competitive interaction of atropine with the nicotinic receptor, and potentiation is also reversed at high atropine concentrations. Steady state effects of acetylcholine and atropine are accounted for by a model for combined receptor occupation and channel block, in which atropine acts on two distinct sites. The first site is associated with noncompetitive ion channel block. The second site is associated with competitive potentiation, which appears to occur when the agonist recognition sites of the receptor are occupied by acetylcholine and atropine. The apparent affinity of atropine for the agonist recognition sites of the α4β4 nicotinic acetylcholine receptor is estimated to be 29.9 μm.
Footnotes
- Received January 22, 1997.
- Accepted July 16, 1997.
-
Send reprint requests to: Dr. Ruud Zwart, Research Institute of Toxicology, Utrecht University, P.O. Box 80.176, NL-3508 TD Utrecht, The Netherlands. E-mail:r.zwart{at}ritox.dgk.ruu.nl
-
This work was supported by Netherlands Organization for Scientific Research (NWO) Grant 903–42-011.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|